Vertex Presents Positive Long-Term Data On CASGEVY™ …
Dec 8, 2024 · BOSTON--(BUSINESS WIRE)--Dec. 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ …
Vertex Announces US FDA Approval of CASGEVY™ …
Jan 16, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration …
Vertex Announces CASGEVY® Reimbursement Agreement for …
2 days ago · - Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in transfusion-dependent beta thalassemia …
Is Vertex Pharmaceuticals a Buy Now That the FDA ... - The …
22 hours ago · Shares of Vertex Pharmaceuticals (VRTX 5.31%) ... Casgevy is a one-and-done treatment that Vertex is marketing and developing in partnership with CRISPR Therapeutics …
Vertex Announces CASGEVY® Reimbursement Agreement for …
2 days ago · LONDON, January 31, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) …
HCP Official Website for CASGEVY® (exagamglogene autotemcel)
CASGEVY is indicated for the treatment of patients aged 12 years and older with: Monitor absolute neutrophil counts (ANC) and manage infections according to standard guidelines and …
CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with …
Long-term data shows durability of Vertex's gene therapy Casgevy
Jun 14, 2024 · Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent …
FDA approves Vertex, CRISPR's Casgevy for beta-thalassemia
Jan 16, 2024 · Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta …
Vertex's Casgevy breaks ground with 1st commercial patient …
Nov 5, 2024 · With the first Casgevy revenues coming in and the company's established cystic fibrosis portfolio firing on all cylinders, Vertex brought in a quarterly haul of $2.77 billion, a 12% …